Document resource
Background and Importance Iron deficiency anaemia (IDA) is the most prevalent nutritional anaemia globally. Although oral iron remains the first-line treatment, absorption is often compromised in patients with gastrointestinal disorders. In such situations, intravenous Ferric Carboxymaltose (FCM) enables a rapid rise in haemoglobin levels. Nevertheless, FCM can cause hypophosphataemia, frequently overlooked due to absent phosphate monitoring. Therefore, regular evaluation and biochemical follow-up are essential to ensure patient safety.Aim and Objectives Analyse the use of intravenous FCM in digestive patients, evaluating their clinical indications, haematological response and the frequency of phosphate monitoring.Material and Methods An observational, retrospective and descriptive study was conducted including all patients from the Digestive Department who received intravenous FCM between January and September 2025. Analytical and treatment-related data were obtained from electronic medical records. The variables collected included sex, age, diagnosis, transferrin saturation index (TSI), haemoglobin before (Hb1) and after treatment (Hb2), administered FCM doses, and whether serum phosphate was measured. For the descriptive analysis, categorical variables were expressed as absolute frequencies and percentages, and continuous variables as medians.Results A total of 58 patients were included: 58,6% men and 39,7% women, with a mean age of 63,9 years. The main indications for FCM were gastrointestinal bleeding (12%), inflammatory bowel disease (3%), and chronic multifactorial anaemia (4,5%). Mean baseline TSI and Hb1 values were 12,5% and 9,08 g/dL, respectively. Most patients (87,9%) received a single 1000 mg FCM dose, six (10,3%) received 1500 mg, and one (1,8%) received 3000 mg as a cumulative dose. After FCM treatment, haemoglobin increased to 10,14 g/dL (Hb2), with a mean increase of +1,05 g/dL. Serum phosphate was measured before infusion in only seven patients (12,1%), despite the known risk of hypophosphataemia.Conclusion and Relevance FCM administration in digestive patients was effective in increasing haemoglobin levels. However, the absence of phosphate monitoring is concerning, as hypophosphataemia is a clinically relevant and potentially underdiagnosed adverse effect. It is recommended to implement a monitoring protocol that includes serum phosphate assessment before and after intravenous iron administration, ensuring safer and more comprehensive management of patients receiving FCM.Conflict of Interest No conflict of interest